Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15022038 | 0.83 | TDP1 (0.52) | TDP1HTTHSD17B10ALOX15CYP1A2 | |
| SCHEMBL1800353 | 0.79 | TDP1 (0.48) | TDP1HTTHSD17B10ALOX15CYP1A2 | |
| SCHEMBL8590777 | 0.79 | HSD17B10 (0.49) | TDP1HTTHSD17B10ALOX15CYP1A2 | |
| SCHEMBL239691 | 0.76 | HTT (0.48) | TDP1HTTHSD17B10ALOX15CYP1A2 | |
| SCHEMBL6954737 | 0.76 | ALOX15 (0.58) | HSD17B10ALOX15CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6256819 | 0.76 | HSD17B10 (0.44) | TDP1HTTHSD17B10ALOX15CYP1A2 | |
| SCHEMBL5458671 | 0.75 | HSD17B10 (0.47) | TDP1HTTHSD17B10ALOX15CYP1A2 | |
| SCHEMBL15401045 | 0.75 | TDP1 (0.48) | TDP1HTTHSD17B10ALOX15CYP1A2 | |
| SCHEMBL1685055 | 0.74 | HSD17B10 (0.61) | HTTHSD17B10ALOX15CYP1A2CYP3A4 | |
| SCHEMBL7684323 | 0.74 | CYP1A2 (0.52) | TDP1HTTHSD17B10ALOX15CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1033971-C | 9-[(substituted glycyl) amido]-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID CO (US) | 1997-02-05 | — | — | CN | claimed |
| CN-1033087-C | Novel 7-(substituted)-8-(substituted-9-[(substituted glycyl) amido]-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID CO (US) | 1996-10-23 | — | — | CN | claimed |
| US-5495031-A | Process for the production of 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1996-02-27 | — | — | US | claimed |
| US-5466684-A | 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1995-11-14 | — | — | US | claimed |
| CN-1087899-A | The 9-[(substituted glycyl) amido)]-6-demethyl-6-deoxidation tsiklomitsin | AMERICAN CYANAMID CO (US) | 1994-06-15 | — | — | CN | claimed |
| CN-1087626-A | The glycyl that novel 7-(replacement)-8-(replacement)-9-[(replaces) amido]-6-demethyl-6-deoxidation tsiklomitsin | AMERICAN CYANAMID CO (US) | 1994-06-08 | — | — | CN | claimed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| EP-3445762-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-13 | — | — | EP | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-11597699-B2 | MEK inhibitors and methods of their use | EXELIXIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| CN-109053523-B | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-05-13 | — | — | US | disclosed |
| US-10980825-B2 | Cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-20 | — | — | US | disclosed |
| WO-2007044515-A1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| US-5639742-A | ANTIBIOTIC; BACTERICIDE | LEE VING JICK (US) | 1997-06-17 | — | — | US | disclosed |
| CN-1033971-C | 9-[(substituted glycyl) amido]-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID CO (US) | 1997-02-05 | — | — | CN | disclosed |
| CN-1033087-C | Novel 7-(substituted)-8-(substituted-9-[(substituted glycyl) amido]-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID CO (US) | 1996-10-23 | — | — | CN | disclosed |
| US-5495032-A | AMINATION OF THE CORRESPONDING HALOGEN CONTAINING COMPOUND | AMERICAN CYANAMID COMPANY (US) | 1996-02-27 | — | — | US | disclosed |
| CN-1087899-A | The 9-[(substituted glycyl) amido)]-6-demethyl-6-deoxidation tsiklomitsin | AMERICAN CYANAMID CO (US) | 1994-06-15 | — | — | CN | disclosed |
| CN-1087626-A | The glycyl that novel 7-(replacement)-8-(replacement)-9-[(replaces) amido]-6-demethyl-6-deoxidation tsiklomitsin | AMERICAN CYANAMID CO (US) | 1994-06-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | TDP1 111/4885HTT 3938/4885HSD17B10 4028/4885 |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | STING1, CGAS, MAVS | TDP1 46/4885HTT 4099/4885HSD17B10 3745/4885 |
| US-10980825-B2 | Cyclic dinucleotide | STING1, CGAS, MAVS | TDP1 46/4885HTT 4099/4885HSD17B10 3745/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | TDP1 111/4885HTT 3938/4885HSD17B10 4028/4885 |
| US-11597699-B2 | MEK inhibitors and methods of their use | BRAF, NRAS, MAP3K20 | TDP1 1707/4885HTT 4807/4885HSD17B10 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.